Shire’s “Buy” Rating Reaffirmed at Deutsche Bank (SHP)
Shire (LON:SHP)‘s stock had its “buy” rating reiterated by equities researchers at Deutsche Bank in a research report issued on Friday, AnalystRatingsNetwork reports. They currently have a GBX 3,850 ($63.20) price objective on the stock. Deutsche Bank’s target price indicates a potential upside of 31.22% from the company’s current price.
Other equities research analysts have also recently issued reports about the stock. Analysts at Credit Suisse reiterated a “neutral” rating on shares of Shire in a research note to investors on Thursday. They now have a GBX 3,200 ($52.53) price target on the stock. Separately, analysts at Liberum Capital raised their price target on shares of Shire from GBX 636 ($10.44) to GBX 649 ($10.65) in a research note to investors on Thursday. They now have a “hold” rating on the stock. Finally, analysts at Barclays raised their price target on shares of Shire from GBX 2,800 ($45.96) to GBX 3,275 ($53.76) in a research note to investors on Wednesday. They now have an “overweight” rating on the stock. One investment analyst has rated the stock with a sell rating, ten have assigned a hold rating, fourteen have assigned a buy rating and one has issued a strong buy rating to the stock. Shire has a consensus rating of “Buy” and a consensus target price of GBX 2,514.86 ($41.28).
Shares of Shire (LON:SHP) traded down 2.33% on Friday, hitting GBX 2934.00. 2,166,898 shares of the company’s stock traded hands. Shire has a 52 week low of GBX 1853.0001 and a 52 week high of GBX 3040.00. The stock has a 50-day moving average of GBX 2853. and a 200-day moving average of GBX 2599.32. The company’s market cap is £16.090 billion.
Shire plc (LON:SHP) is a specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.